https://european-biotechnology.net/wp-content/uploads/2025/10/NOVARTIS-HQ_508908319_Michael-Derrer-Fuchs-e1761645824248.jpg538958Thomas Gabrielczyk/wp-content/uploads/2019/12/ebn-1-300x135.pngThomas Gabrielczyk2026-03-20 12:55:512026-03-20 12:55:51Novartis strikes another billion-dollar oncology deal with acquisition of an early PI3Kalpha oral therapy
https://european-biotechnology.net/wp-content/uploads/2025/09/Genetech_320984427_b8PYYp7YaXx5WBi6WwRXFIg8OupDixUA-e1756802020857.jpg5631000Thomas Gabrielczyk/wp-content/uploads/2019/12/ebn-1-300x135.pngThomas Gabrielczyk2026-03-18 08:29:232026-03-18 08:29:23Swiss Roche builds its own AI factory with NVIDIA – with Genentech in California
https://european-biotechnology.net/wp-content/uploads/2026/03/mansionhouse-sciencevillage-1030x687-1.jpg6871030Thomas Gabrielczyk/wp-content/uploads/2019/12/ebn-1-300x135.pngThomas Gabrielczyk2026-03-17 13:28:022026-03-17 13:28:02Mestag Therapeutics raises $40M and adds two senior biotech executives as lead cancer program nears the clinic
https://european-biotechnology.net/wp-content/uploads/2025/09/NRG_1650536385_REE9VqiEAxf9lNiEm5SSpvIR9FyVo8Ko-e1757312244435.jpg480960Thomas Gabrielczyk/wp-content/uploads/2019/12/ebn-1-300x135.pngThomas Gabrielczyk2026-03-17 12:44:582026-03-17 12:44:58Delivering drugs into cells: Seed funding for German iDEL and its ‘wonder shuttle’
https://european-biotechnology.net/wp-content/uploads/2026/03/matt-paul-catalano-0QEG_xOoY7Y-unsplash-1030x687-1.jpg6871030Thomas Gabrielczyk/wp-content/uploads/2019/12/ebn-1-300x135.pngThomas Gabrielczyk2026-03-13 12:22:312026-03-13 12:22:31Owkin spins out AI diagnostics startup Waiv with $33M financing
https://european-biotechnology.net/wp-content/uploads/2026/03/freeze-frame-min-goldensite-valanx.jpg540960Thomas Gabrielczyk/wp-content/uploads/2019/12/ebn-1-300x135.pngThomas Gabrielczyk2026-03-12 16:09:502026-03-12 16:09:50Vienna’s VALANX secures €3 million to push preclinical ADC programme in breast cancer
https://european-biotechnology.net/wp-content/uploads/2026/03/moritz-mentges-XZuqMUiSdgc-unsplash-1030x688-1.jpg6881030Thomas Gabrielczyk/wp-content/uploads/2019/12/ebn-1-300x135.pngThomas Gabrielczyk2026-03-12 13:00:112026-03-12 13:00:11Enodia strikes up to $127m deal for Kezar’s preclinical protein degradation assets
https://european-biotechnology.net/wp-content/uploads/2026/03/Evotec_HQ.jpeg540960Thomas Gabrielczyk/wp-content/uploads/2019/12/ebn-1-300x135.pngThomas Gabrielczyk2026-03-12 08:08:432026-03-12 08:08:43Hamburg CRO Evotec to cut costs further and reduce workforce by 800
https://european-biotechnology.net/wp-content/uploads/2026/03/getty-images-PGTMJ-rZOkQ-unsplash-1030x579-1.jpg5791030Thomas Gabrielczyk/wp-content/uploads/2019/12/ebn-1-300x135.pngThomas Gabrielczyk2026-03-10 16:07:552026-03-10 16:07:55Ipsen withdraws cancer drug following safety concerns
